Andrew Wardley
Overview
Explore the profile of Andrew Wardley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
4311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Regan M, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, et al.
Lancet Oncol
. 2011 Oct;
12(12):1101-8.
PMID: 22018631
Background: Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up....
22.
Coombes R, Bliss J, Espie M, Erdkamp F, Wals J, Tres A, et al.
J Clin Oncol
. 2011 Jul;
29(24):3247-54.
PMID: 21768453
Purpose: The Docetaxel Epirubicin Adjuvant (DEVA) trial evaluated the efficacy and toxicity of incorporating docetaxel after epirubicin to create a sequential anthracycline-taxane regimen in early breast cancer. Patients And Methods:...
23.
Colleoni M, Giobbie-Hurder A, Regan M, Thurlimann B, Mouridsen H, Mauriac L, et al.
J Clin Oncol
. 2011 Feb;
29(9):1117-24.
PMID: 21321298
Purpose: Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence...
24.
Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J, et al.
Lancet
. 2010 Jul;
376(9737):235-44.
PMID: 20609467
Background: Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced synthetic lethality in BRCA-deficient cells. A maximum tolerated dose and initial signal of efficacy in BRCA-deficient ovarian cancers have...
25.
Gianni L, Llado A, Bianchi G, Cortes J, Kellokumpu-Lehtinen P, Cameron D, et al.
J Clin Oncol
. 2010 Feb;
28(7):1131-7.
PMID: 20124183
Purpose: Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the antitumor activity and...
26.
Baselga J, Gelmon K, Verma S, Wardley A, Conte P, Miles D, et al.
J Clin Oncol
. 2010 Feb;
28(7):1138-44.
PMID: 20124182
Unlabelled: PURPOSE; Pertuzumab, a human epidermal growth factor receptor 2 (HER2) -targeted monoclonal antibody, potently inhibits HER2 dimerization and HER-mediated signaling pathways. Pertuzumab and the approved HER2-targeted monoclonal antibody trastuzumab...
27.
Leyland-Jones B, Colomer R, Trudeau M, Wardley A, Latreille J, Cameron D, et al.
J Clin Oncol
. 2009 Dec;
28(6):960-6.
PMID: 20026806
PURPOSE Pharmacokinetics (PKs) and safety results from phase II/III trials suggest that, if high trastuzumab serum concentrations are reached early during treatment for human epidermal growth factor receptor 2 (HER2)-positive...
28.
Molassiotis A, Brearley S, Saunders M, Craven O, Wardley A, Farrell C, et al.
J Clin Oncol
. 2009 Nov;
27(36):6191-8.
PMID: 19917849
Purpose: To assess the effectiveness of a symptom-focused home care program in patients with cancer who were receiving oral chemotherapy in relation to toxicity levels, anxiety, depression, quality of life,...
29.
Kaufman B, Mackey J, Clemens M, Bapsy P, Vaid A, Wardley A, et al.
J Clin Oncol
. 2009 Sep;
27(33):5529-37.
PMID: 19786670
Purpose: TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/hormone receptor-copositive metastatic...
30.
Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, OReilly S, et al.
Lancet
. 2009 May;
373(9676):1681-92.
PMID: 19447249
Background: Incorporation of a taxane as adjuvant treatment for early breast cancer offers potential for further improvement of anthracycline-based treatment. The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after...